BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, April 24, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Nov. 11, 2008
View Archived Issues
Inhibition of ErbB3 receptor by EZN-3920 shows antitumor activity in preclinical studies
Read More
MTD established in a phase I advanced cancer study of oral c-Met inhibitor ARQ-197
Read More
Novel class of antibacterial pyrrolamides targeting DNA gyrase identified
Read More
ARRY-162 safe, affects biomarkers in phase I studies
Read More
Increased exposure seen with deuterated linezolid compared with linezolid in vivo
Read More
Allergan reviews Q3 accomplishments
Read More
ArQule and Daiichi Sankyo enter strategic R&D cancer program
Read More
Azur and Elan sign agreement to develop once-daily clozapine
Read More
EntreMed meets primary efficacy endpoint in phase I/II NSCLC trial
Read More
ProtoKinetix receives independent confirmation of AAGP antiinflammatory action
Read More
FDA clears Celgene's placenta-derived stem cells for first clinical study
Read More
FDA and DOR agree on design of phase III study of orBec in GI GVHD
Read More
Dosing is initiated in INFORM-1 clinical trial of R-7227 and R-7128 for HCV
Read More
Aradigm announces results from clinical trial of inhaled treprostinil with AERx inhaler
Read More
Amgen provides pipeline update at recent investors meeting
Read More
GSK and XenoPort plan to withdraw and resubmit Solzira NDA for RLS
Read More
Xoma restructures drug development collaboration with Novartis
Read More
Insmed gains royalty-free worldwide rights for Iplex for ALS
Read More
TorreyPines sells AD genetics program to Eisai, enabling advancement of clinical-stage assets
Read More
Optimer presents data from North American phase III OPT-80 study
Read More
Recent patents disclose novel therapeutic agents for asthma and other indications
Read More
New treatment options for urological disorders reported in recent patents
Read More
Novel agents for psychiatric disorders described in recent patent literature
Read More